Borane‐Catalyzed Tandem Cyclization/Hydrosilylation Towards Enantio‐ and Diastereoselective Construction of trans ‐2,3‐Disubstituted‐1,2,3,4‐Tetrahydroquinoxalines
Angewandte Chemie International Edition · 07.08.2023 · 62 (32)
DOI: 10.1002/anie.202305449 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, online erschienen am 03.07.2023. Verfasst von Zhenli Luo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Renmin University of China, 100872, Beijing, China. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 112 Literaturangaben. Gefördert von: Division of Chemistry, National Natural Science Foundation of China, Beijing National Laboratory for Molecular Sciences.
Abstract (Originalsprache)
Recent years have witnessed marked progress in the efficient synthesis of various enantioenriched 1,2,3,4‐tetrahydroquinoxalines. However, enantio‐ and diastereoselective access to trans ‐2,3‐disubstituted 1,2,3,4‐tetrahydroquinoxalines remains much less explored. Herein we report that a frustrated Lewis pair‐based catalyst generated via in situ hydroboration of 2‐vinylnaphthalene with HB(C 6 F 5 ) 2 allows for the one‐pot tandem cyclization/hydrosilylation of 1,2‐diaminobenzenes and 1,2‐diketones with commercially available PhSiH 3 to exclusively afford trans ‐2,3‐disubstituted 1,2,3,4‐tetrahydroquinoxalines in high yields with excellent diastereoselectivities (>20 : 1 dr). Furthermore, this reaction can be rendered asymmetric by using an enantioenriched borane‐based catalyst derived from HB(C 6 F 5 ) 2 and a binaphthyl‐based chiral diene to give rise to enantioenriched trans ‐2,3‐disubstituted 1,2,3,4‐tetrahydroquinoxalines in high yields with almost complete diastereo‐ and enantiocontrol (>20 : 1 dr, up to >99 % ee). A wide substrate scope, good tolerance of diverse functionality and up to 20‐gram scale production are demonstrated. The enantio‐ and diastereocontrol are achieved by the judicious choice of borane catalyst and hydrosilane. The catalytic pathway and the origin of the excellent stereoselectivity are elucidated by mechanistic experiments and DFT calculations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Chemistry, Renmin University of China, 100872, Beijing, China.
- State Key Laboratory of Chemical Resource Engineering, Institute of Computational Chemistry, College of Chemistry, Beijing University of Chemical Technology, 100029, Beijing, China.
- Roy and Diana Vagelos Laboratories, Penn/Merck Laboratory for High-Throughput Experimentation, Department of Chemistry, University of Pennsylvania, 231 South 34th Street, PA 19104-6323, Philadelphia, USA.
- Beijing National Laboratory for Molecular Sciences and Institute of Chemistry, Chinese Academy of Sciences, 100190, Beijing, China.
Förderung
- Division of Chemistry
- National Natural Science Foundation of China
- Beijing National Laboratory for Molecular Sciences
Zitieren
APA
Luo, Z., Li, Z., Zhao, H., Yang, J., Xu, L., Lei, M., Fan, Q., & Walsh, P. J. (2023). Borane‐Catalyzed Tandem Cyclization/Hydrosilylation Towards Enantio‐ and Diastereoselective Construction of trans ‐2,3‐Disubstituted‐1,2,3,4‐Tetrahydroquinoxalines. Angewandte Chemie International Edition, 62(32). https://doi.org/10.1002/anie.202305449
Vancouver
Luo Z, Li Z, Zhao H, Yang J, Xu L, Lei M, et al. Borane‐Catalyzed Tandem Cyclization/Hydrosilylation Towards Enantio‐ and Diastereoselective Construction of trans ‐2,3‐Disubstituted‐1,2,3,4‐Tetrahydroquinoxalines. Angewandte Chemie International Edition. 2023;62(32). doi:10.1002/anie.202305449
BibTeX
@article{Luo2023,
author = {Luo, Zhenli and Li, Zhewei and Zhao, Haoqiang and Yang, Ji and Xu, Lijin and Lei, Ming and Fan, Qinghua and Walsh, Patrick J},
title = {Borane‐Catalyzed Tandem Cyclization/Hydrosilylation Towards Enantio‐ and Diastereoselective Construction of trans ‐2,3‐Disubstituted‐1,2,3,4‐Tetrahydroquinoxalines},
journal = {Angewandte Chemie International Edition},
year = {2023},
volume = {62},
number = {32},
doi = {10.1002/anie.202305449}
}
EUVIMED